发布时间: 2026 - 05 - 09
BEIJING, CHINA, May 8, 2026 – Beijing Biostar Pharmaceuticals Co., Ltd. (2563.HK, "Biostar Pharma"), a biopharmaceutical company leveraging its synthetic biology R&D platform to develop innovative anticancer drugs with proprietary intellectual property, today announced that Baheal Pharmaceutical (301015.SZ) has subscribed to 25 million new shares issued by Biostar Pharma. Upon completion of the issuance, Biostar Pharma will receive HK$100 million in subscription proceeds, and Baheal Pharmaceutical will hold an aggregate of 29,170,800 shares, representing 7.49% of the Co...
浏览次数:3
发布时间: 2026 - 05 - 06
Recently, the results of the "RZ U45" China's Best Young Investment Figures selection, hosted by RZ Media and RZ Research, were grandly announced. Zhu Pai, CEO of Efung Capital, stood out among numerous candidates with his profound industry insight and successfully made the list.The "RZ U45" is an authoritative selection in China's equity investment industry initiated by RZ Media and RZ Research, aiming to identify outstanding young investment leaders under the age of 45 who have demonstrated exceptional performance in China's equity investment sector. The selec...
浏览次数:3
发布时间: 2026 - 04 - 30
Today, Investors.com officially released its "Investors.com 2026·54 Best Young Investors List". Mr. Pai Zhu, CEO of Efung Capital, stood out among numerous competitors and was named to the prestigious list, thanks to his profound industry insights and continuous deep cultivation in the biopharmaceutical field.This list is initiated by Investors.com in collaboration with the Investors Research Institute. It aims to recognize a new generation of investors who possess a unique combination of technological acumen, industrial insight, and innovative action du...
浏览次数:4
发布时间: 2026 - 04 - 30
On April 28, the Political Bureau of the CPC Central Committee held a meeting to analyze the economic situation and deploy work priorities. The meeting emphasized the need to implement, with precision and effectiveness, a more proactive fiscal policy and a moderately accommodative monetary policy, to boost domestic demand and drive industrial upgrading, and to strive for a good start to the 15th Five-Year Plan period. This has sent a clear signal to the market: capital will be directed toward technological innovation fields aligned with national strategies, particularly "hard tech" d...
浏览次数:3
85页次1/22首页PREV12345678910...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务